{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huang C"],"funding":["Guangdong Foundation of Medical Science","National Science Foundation of China","National Natural Science Foundation of China","Guangzhou Foundation of Science and Technology"],"pagination":["e24584"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9396162"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(8)"],"pubmed_abstract":["<h4>Background</h4>The development of cardiac fibrosis involves the activation of cardiac fibroblasts (CFs) and their differentiation into myofibroblasts, which leads to the disruption of the extracellular matrix network. In the past few years, microRNAs (miRNA) have been described as potential targets for treating cardiac diseases. Although miR-338-3p has been shown to participate in the development of carcinoma, whether it affects cardiac fibrosis is unclear.<h4>Methods</h4>We examined the expression profiles of microRNAs in left ventricular samples of heart failure mice established by thoracic aortic constriction (TAC). Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect the expression of miR-338-3p. CCK-8 assay/Transwell migration assay w"],"journal":["Journal of clinical laboratory analysis"],"pubmed_title":["MicroRNA-338-3p as a therapeutic target in cardiac fibrosis through FGFR2 suppression."],"pmcid":["PMC9396162"],"funding_grant_id":["No. 202102080011","No. 81300230","No. 202102020500","No. C2019043"],"pubmed_authors":["Wu Z","Huang C","Wu M","He Y","Feng Z","Wang R","Lu J","Wu Y","Xu J","Ma W"],"additional_accession":[]},"is_claimable":false,"name":"MicroRNA-338-3p as a therapeutic target in cardiac fibrosis through FGFR2 suppression.","description":"<h4>Background</h4>The development of cardiac fibrosis involves the activation of cardiac fibroblasts (CFs) and their differentiation into myofibroblasts, which leads to the disruption of the extracellular matrix network. In the past few years, microRNAs (miRNA) have been described as potential targets for treating cardiac diseases. Although miR-338-3p has been shown to participate in the development of carcinoma, whether it affects cardiac fibrosis is unclear.<h4>Methods</h4>We examined the expression profiles of microRNAs in left ventricular samples of heart failure mice established by thoracic aortic constriction (TAC). Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect the expression of miR-338-3p. CCK-8 assay/Transwell migration assay w","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-06-01T02:20:51.863Z","creation":"2025-04-19T09:31:54.565Z"},"accession":"S-EPMC9396162","cross_references":{"pubmed":["35792028"],"doi":["10.1002/jcla.24584"]}}